Title
Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening—United States, 2016
Document Type
Article
Publication Date
6-1-2019
Publication Title
Diagnostic Microbiology and Infectious Disease
Abstract
© 2018 Elsevier Inc. Perinatal group B Streptococcus (GBS) disease prevention guidelines in 2010 allowed for processing of screening specimens by nucleic acid amplification tests (NAATs); however, the extent of NAAT use is unknown. A 2016 laboratory survey sent to 10 surveillance sites found that 18.7% of responding laboratories offered NAAT for GBS screening (antenatal only: 7.3%; intrapartum only: 4.1%; both: 3.4%).
Volume
94
Issue
2
First Page
157
Last Page
159
Recommended Citation
Fay K, Almendares O, Robinson-Dunn B, Schrag S. Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening-United States, 2016. Diagn Microbiol Infect Dis. 2019 Jun;94(2):157-159. doi: 10.1016/j.diagmicrobio.2018.11.026. Epub 2018 Dec 11. PMID: 30642719.
DOI
10.1016/j.diagmicrobio.2018.11.026
ISSN
07328893
PubMed ID
30642719